Physician profile
Christopher James Roach
NPI 1144219510
$3,655.64
in general payments reported to CMS, 2019-2025
10 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,360 · 2020: $123 · 2021: $698 · 2022: $240 · 2023: $24.31 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medinc of Texas | $2,280.45 | 2019-2021 | |
| Stryker Corporation | $300.58 | 2020-2022 | |
| Zimmer Biomet Holdings, INC. | $240.54 | 2019-2021 | |
| Pacira Therapeutics, INC. | $217.06 | 2019-2021 | |
| Peerless Surgical INC. | $209.98 | 2025 | |
| Bone Support INC. | $137.90 | 2021 | |
| Vericel Corporation | $121.91 | 2021 | |
| Heron Therapeutics, INC. | $62.50 | 2022 | |
| Smith+Nephew, INC. | $60.41 | 2021 | |
| Seapearl East, INC | $24.31 | 2023 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.